This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACLX Arcellx (ACLX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Arcellx Stock (NASDAQ:ACLX) Get Arcellx alerts:Sign Up Key Stats Today's Range$114.99▼$115.1350-Day Range$113.76▼$115.1052-Week Range$47.86▼$115.13Volume14.67 million shsAverage Volume1.50 million shsMarket Capitalization$6.73 billionP/E RatioN/ADividend YieldN/APrice Target$111.87Consensus RatingHold Company Overview Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers. The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region. Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.AI Generated. May Contain Errors. Read More Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACLX Stock News HeadlinesGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celApril 28, 2026 | businesswire.comGilead extends Arcellx tender offer againApril 17, 2026 | seekingalpha.comSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their historic runs - says the SpaceX IPO is set for June 12 and could be the most anticipated market debut ever. Brown is showing investors how to legally claim a stake before the company goes public, ahead of what chief market strategist Shay Boloor called 'the craziest IPO in the history of the stock market.'June 4 at 1:00 AM | Brownstone Research (Ad)Truist Financial Keeps Their Hold Rating on Arcellx Inc (ACLX)April 10, 2026 | theglobeandmail.comAssessing Arcellx (ACLX) Valuation After Strong Multi‑Year Share Price GainsApril 8, 2026 | finance.yahoo.comAssessing Arcellx (ACLX) Valuation After Strong Multi Period Share Price MomentumMarch 25, 2026 | finance.yahoo.comArcellx Inc.March 24, 2026 | barrons.comHalper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their ShareholdersMarch 19, 2026 | globenewswire.comSee More Headlines ACLX Stock Analysis - Frequently Asked Questions How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings data on Thursday, February, 26th. The company reported ($1.01) EPS for the quarter, meeting analysts' consensus estimates of ($1.01). The business had revenue of $1.65 million for the quarter, compared to the consensus estimate of $13.40 million. Arcellx had a negative trailing twelve-month return on equity of 55.42% and a negative net margin of 1,027.26%. When did Arcellx IPO? Arcellx (ACLX) raised $132 million in an IPO on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share. Who are Arcellx's major shareholders? Arcellx's top institutional investors include Bank of America Corp DE (0.77%), Affinity Asset Advisors LLC (0.62%), Gabelli Funds LLC (0.33%) and GABELLI & Co INVESTMENT ADVISERS INC. (0.26%). Insiders that own company stock include Jill Carroll, Rami Elghandour, Christopher Heery, Michelle Gilson, Olivia C Ware, Olivia C Ware and Kavita Patel. View institutional ownership trends. What other stocks do shareholders of Arcellx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings2/26/2026Today6/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACLX CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees80Year Founded2015Price Target and Rating Average Price Target for Arcellx$111.87 High Price Target$133.00 Low Price Target$82.00 Potential Upside/Downside-2.8%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$228.93 million Net Margins-1,027.26% Pretax Margin-1,026.94% Return on Equity-55.42% Return on Assets-36.24% Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio4.44 Sales & Book Value Annual Sales$22.29 million Price / Sales301.95 Cash FlowN/A Price / Cash FlowN/A Book Value$6.96 per share Price / Book16.53Miscellaneous Outstanding Shares58,480,000Free Float53,597,000Market Cap$6.73 billion OptionableOptionable Beta0.25 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ACLX) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredMassive Update to My SpaceX IPO ThesisJeff Brown predicted SpaceX would be the biggest and most anticipated IPO ever - part of Elon's larger plan to...Brownstone Research | SponsoredYour 401k Is Exit LiquidityMichael Burry, who called the 2008 collapse, responded to a post by veteran Fidelity manager George Noble with...Americas Gold Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
